RESEARCH
LCS101 Formula
Clinically researched for supportive care during oncology treatments
Research Overview
The LCS101 research program was designed to examine how a multi-component botanical formula may support patients during oncology care while remaining compatible with standard treatments. The formula has been evaluated in clinical and preclinical studies focusing on chemotherapy-related side effects, quality of life, immune activity, selective effects in cancer cell models, and interaction with chemotherapy and radiation therapy.
Research activity connected to LCS101 has involved oncologists, biologists, immunologists, and academic researchers from medical centers and university laboratories in Israel, the United States, and Europe, including MD Anderson, Harvard Medical School, Bar-Ilan University Cancer Research Center, Sheba Medical Center, Ichilov Medical Center, Jagiellonian University, Miami Children’s Hospital, and Refuot Integrative Medical Center.
Findings from the LCS101 research program have been published in peer-reviewed medical journals and presented in professional scientific and medical forums.
Research Areas
Support During Chemotherapy
LCS101 was evaluated in a randomized, controlled, double-blind clinical trial in breast cancer patients receiving chemotherapy at Sourasky Medical Center in Tel Aviv. Patients received either chemotherapy with LCS101 or chemotherapy with placebo, beginning two weeks before treatment and continuing through the final chemotherapy cycle.
The study focused on chemotherapy-related hematological toxicities, including reductions in white and red blood cell counts.
Key finding: 82% of patients taking LCS101 did not experience a decrease in white blood cell or red blood cell counts.
Published in: The Oncologist
Study type: Randomized, controlled, double-blind clinical trial
Read publication >>
Quality Of Life During Treatment
LCS101 was also studied in breast cancer patients receiving chemotherapy, with a focus on quality of life and treatment-related symptoms such as fatigue, weakness, nausea, vomiting, pain, decreased appetite, and digestive discomfort.
The findings suggest a supportive role for LCS101 in helping patients better tolerate the burden of treatment.
Key finding: 89% of patients reported improvement in quality of life and reduction of chemotherapy-related symptoms.
Published in: Integrative Medicine Insights
Study type: Clinical report
Read publication >>
Selective Activity In Cancer Cell Models
Preclinical research evaluated the effects of LCS101 on breast, colon, and prostate cancer cell lines, alongside non-tumorigenic human epithelial cells. The purpose was to examine whether the formula demonstrated selective biological activity in cancer-related models.
The study reported activity against several cancer cell lines while also showing protective effects in non-tumorigenic cells exposed to chemotherapy-related stress.
Key finding: LCS101 selectively induced cancer cell death in several cancer cell-line models while showing protective effects on non-tumorigenic cells.
Published in: International Journal of Oncology
Study type: Preclinical in vitro study
Read publication >>
Immune-Modulating Activity
The effect of LCS101 on the immune system was evaluated in preclinical research examining components of innate and adaptive immunity. This work explored the broader biological rationale for using LCS101 in supportive oncology settings.
The findings suggested that LCS101 may have immune-modulating activity across multiple immune pathways.
Key finding: LCS101 demonstrated immune-modulating activity involving both innate and adaptive immune responses.
Published in: OncoTargets and Therapy
Study type: Preclinical immunology study
Read publication >>
Compatibility With Chemotherapy
A key concern in integrative oncology is whether a botanical formula might interfere with chemotherapy. LCS101 was evaluated in preclinical studies together with multiple chemotherapy agents across different cancer cell-line models.
The findings showed that LCS101 did not reduce the cytotoxic effect of the chemotherapy agents tested. In several models, its addition was associated with increased cancer cell death.
Key finding: LCS101 did not reduce chemotherapy cytotoxicity in the models tested.
Published in: Journal of Cancer Science & Therapy
Study type: Preclinical chemotherapy interaction study
Read publication >>
Compatibility With Radiation Therapy
LCS101 was also evaluated in a preclinical study examining its interaction with radiation therapy in cancer cell-line models. Cancer cells were irradiated and then exposed to incremental doses of LCS101 to assess combined effects.
The study reported an apparent additive effect when LCS101 was added to irradiated cancer cells, suggesting potential compatibility in this setting.
Key finding: LCS101 showed an apparent additive effect in irradiated cancer cell models.
Published in: Journal of Cancer Research and Clinical Oncology
Study type: Preclinical radiation interaction study
Read publication >>
Why This Research Matters
Patients undergoing cancer treatment often face multiple challenges at once, including blood-count suppression, fatigue, appetite loss, digestive symptoms, immune stress, and reduced quality of life. LCS101 was developed for this complex supportive-care setting.
Rather than focusing on a single pathway, the LCS101 research program examined a broader clinical picture: patient well-being, hematological support, immune activity, cellular response, and compatibility with standard cancer treatments.
Educational Notice
LCS101 is not intended to replace conventional oncology treatment. Patients receiving chemotherapy, radiation therapy, immunotherapy, or other cancer treatment should consult their oncologist or qualified healthcare provider before using any supportive-care product.
Scientific Validation
LifeBiotic’s work includes peer-reviewed publications and presentations at scientific forums including SIO and UNESCO-convened discussions.
